What are the treatments for prostate cancer? CRPC ifARPI fails
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Reviewed by Dr. Chris Apfel, MD/PhD (UCSF)
Prostate Cancer Treatments: When ARPI Therapy Doesn't Work
I appreciate your specific question about treatment options when androgen receptor pathway inhibitor (ARPI) therapy—medications that block hormone signals fueling prostate cancer—hasn't been effective.
Treatment Options After ARPI Failure
According to the NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer (2024), when hormone-blocking treatments don't work, several evidence-based options are available for castration-resistant prostate cancer (CRPC):
1. Biomarker-Targeted Therapy (PARP Inhibitors)
These medications target specific genetic mutations in cancer cells:
- Rucaparib (Rubraca)
- Olaparib (Lynparza)
- Niraparib and abiraterone (Akeega)
- Talazoparib (Talzenna)
The NCCN notes that about 1 in 4 patients with metastatic hormone-resistant prostate cancer have genetic mutations (like BRCA1 or BRCA2) that these drugs can target. Your doctor will perform molecular tumor testing to see if your cancer has these mutations.
2. Radiopharmaceuticals (Targeted Radiation)
These are radioactive medicines injected into your bloodstream that find and kill cancer cells:
-
Lutetium-177 (Pluvicto): Targets a protein called PSMA on prostate cancer cells. Given as an IV infusion every 6 weeks for up to 6 doses. Requires a PSMA-PET scan first to confirm eligibility.
-
Radium-223 (Xofigo): Used when cancer has spread to bones but not other organs. Given as monthly injections for 6 months. Often combined with bone-protecting medications.
3. Radiation Therapy
External beam radiation therapy (EBRT) uses high-energy rays to target cancer cells precisely, particularly useful for regional disease or bone metastases.
Important Next Steps
Your oncologist should:
- Order genetic testing to determine if PARP inhibitors are appropriate
- Discuss which option best fits your specific cancer stage and location
- Review potential side effects with you
- Monitor your response with PSA levels and imaging
This is a personalized decision—what works best depends on your cancer's specific characteristics, where it has spread, and your overall health.
Would you like me to explain any of these treatments in more detail?
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2